Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002

Detalhes bibliográficos
Autor(a) principal: Ferreira-Dos-Santos, Guilherme
Data de Publicação: 2018
Outros Autores: Sousa, David Cordeiro, Costa, João, Vaz-Carneiro, António
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433
Resumo: Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.
id RCAP_3b040cb1a8d069e51396ebfacbe4dd61
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/10433
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002Análise da Revisão Cochrane: Pregabalina no Tratamento da Dor Crónica Moderada a Grave em Adultos com Fibromialgia. Cochrane Database Syst Rev. 2016;9:CD011790 e 2016;4:CD009002Chronic PainFibromyalgiaPregabalinRandomized Controlled TrialsSystematic ReviewDor CrónicaEnsaios Clínicos AleatorizadosFibromialgiaPregabalinaRevisão SistemáticaFibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.A fibromialgia é uma doença caracterizada por dor generalizada, com mais de três meses de duração, com dor à palpação em pelo menos 11 de 18 pontos anatomicamente definidos. Um elevado número de doentes com fibromialgia sofre de dor moderada a grave durante vários anos, para a qual os analgésicos convencionais se mostraram ineficazes, de tal forma que foram substituídos por antidepressivos tricíclicos, inibidores seletivos da recaptação da serotonina e noradrenalina e anticonvulsivantes, como a pregabalina e a gabapentina. A pregabalina é um fármaco anti-epilético aprovado para o tratamento da fibromialgia nos Estados Unidos da América, cujo mecanismo de ação se assemelha ao da gabapentina, com efeitos anticonvulsivante, analgésico e ansiolítico. Nesta revisão sistemática Cochrane os autores incluíram um total de oito ensaios clínicos aleatorizados, controlados por placebo, com baixo risco global de viés, que estudaram o efeito da administração de uma dose diária de pregabalina no tratamento da dor crónica moderada a grave, em doentes adultos com fibromialgia. Dos principais resultados desta revisão sistemática destacam-se o efeito substancial que uma dose diária de 300 a 600 mg de pregabalina teve na diminuição da intensidade da dor moderada a grave, numa minoria dos doentes adultos com fibromialgia, durante um período de follow-up de 12 a 26 semanas, bem como a elevada incidência de eventos adversos associados ao tratamento, a maioria dos quais bem tolerados. Neste artigo sumarizam-se e discutem-se os principais resultados e conclusões desta revisão sistemática, bem como as suas implicações para a prática clínica diária. Ordem dos Médicos2018-08-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433oai:ojs.www.actamedicaportuguesa.com:article/10433Acta Médica Portuguesa; Vol. 31 No. 7-8 (2018): July-August; 376-381Acta Médica Portuguesa; Vol. 31 N.º 7-8 (2018): Julho-Agosto; 376-3811646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/5462https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10177https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10494Direitos de Autor (c) 2018 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessFerreira-Dos-Santos, GuilhermeSousa, David CordeiroCosta, JoãoVaz-Carneiro, António2022-12-20T11:05:59Zoai:ojs.www.actamedicaportuguesa.com:article/10433Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:53.217051Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
Análise da Revisão Cochrane: Pregabalina no Tratamento da Dor Crónica Moderada a Grave em Adultos com Fibromialgia. Cochrane Database Syst Rev. 2016;9:CD011790 e 2016;4:CD009002
title Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
spellingShingle Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
Ferreira-Dos-Santos, Guilherme
Chronic Pain
Fibromyalgia
Pregabalin
Randomized Controlled Trials
Systematic Review
Dor Crónica
Ensaios Clínicos Aleatorizados
Fibromialgia
Pregabalina
Revisão Sistemática
title_short Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
title_full Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
title_fullStr Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
title_full_unstemmed Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
title_sort Analysis of the Cochrane Review: Pregabalin for Pain in Fibromyalgia in Adults. Cochrane Database Syst Rev. 2016;9:CD011790 and 2016;4:CD009002
author Ferreira-Dos-Santos, Guilherme
author_facet Ferreira-Dos-Santos, Guilherme
Sousa, David Cordeiro
Costa, João
Vaz-Carneiro, António
author_role author
author2 Sousa, David Cordeiro
Costa, João
Vaz-Carneiro, António
author2_role author
author
author
dc.contributor.author.fl_str_mv Ferreira-Dos-Santos, Guilherme
Sousa, David Cordeiro
Costa, João
Vaz-Carneiro, António
dc.subject.por.fl_str_mv Chronic Pain
Fibromyalgia
Pregabalin
Randomized Controlled Trials
Systematic Review
Dor Crónica
Ensaios Clínicos Aleatorizados
Fibromialgia
Pregabalina
Revisão Sistemática
topic Chronic Pain
Fibromyalgia
Pregabalin
Randomized Controlled Trials
Systematic Review
Dor Crónica
Ensaios Clínicos Aleatorizados
Fibromialgia
Pregabalina
Revisão Sistemática
description Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.
publishDate 2018
dc.date.none.fl_str_mv 2018-08-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433
oai:ojs.www.actamedicaportuguesa.com:article/10433
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/10433
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/5462
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10177
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10433/10494
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2018 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2018 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 31 No. 7-8 (2018): July-August; 376-381
Acta Médica Portuguesa; Vol. 31 N.º 7-8 (2018): Julho-Agosto; 376-381
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1817550466019491840